Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona. After a long slog, these cases are now moving forward.
The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The second trial, Divelbliss v. C.R. Bard, led to a $40 million verdict. It involved an alleged fracture of a silicone Groshong catheter. The third trial, Lattanzio, ended in a defense verdict on October 30, 2026, in a catheter infection case. Five bellwether trials are scheduled through February 2027. The early results have been very different, and our lawyers remain bullish on well-documented fracture, migration, and embolization cases.
This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim.










